Bror Thomas Pollare

3i Nordic Plc (3i Nordic) is the Swedish venture capital subsidiary of 3i Group Plc (LSE: III) in Great Britain. Formerly known as Atle AB, founded in 1993, the firm was acquired by 3i in 2001 and renamed 3i Nordic. Located in Stockholm, 3i Nordic utilizes specialized 3i Group resources to provide financial experience, sector knowledge, company management practice and access to 3i's network of international contacts to investee companies. 3i Nordic is part of the 3i Nordic investment team which includes investment professionals from the Helsinki and Copenhagen offices.

Xellia Pharmaceuticals ApS manufactures pharmaceutical products. Its products include pharmaceutical ingredients, finished dosage forms and novel anti infective pipeline. The company was founded in 1959 and is headquartered in Copenhagen, Denmark.

Premacure AB owns shares and acquires securities, patents, rights and licenses from other businesses. It is also involved in biotechnology and medicine. The company is headquartered in Stockholm, Sweden.

Global Medical Investments GMI AB establishes and operates cancer centers in developing countries. It engages in the development and support of cancer management programs and cancer treatment clinics. The firm is an investment and project development company. It also secures contracts with health insurance companies and healthcare providers for private and state-run companies and government insurance agencies. The company was founded by Bror Thomas Pollare on July 24, 2009 and is headquartered in Solna, Sweden.

Psilox AB engages in the manufacture and application of bio ceramic materials. It offers calcium phosphate microspheres used in treatments in dentistry and medicine. The company was founded by Håkan Gunnar Engqvist and Wei Xia on May 29, 2013 and is headquartered in Uppsala, Sweden.

QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden.

SSI Diagnostica A/S develops, produces, and sells in-vitro diagnostic products for clinical microbiology, veterinary diagnostics, food control, as well as environmental and hygiene control. The firm supplies a range of pneumococcal antigens and serotype specific capsular polysaccharides. The firm also markets antisera, bacterial strains, rapid tests, and animal blood products. The company was founded in 1998 and is headquartered in Hillerod, Denmark.

Sinfonia Biotherapeutics AB is a Swedish clinical stage company that develops biologics for neuropathic pain. The private company is based in Huddinge, Sweden.

Gamma Knife Center Ecuador SA engages in the management of a healthcare institution. The firm specializes in the provision of stereotactic radiosurgery through a Gamma Knife unit to treat patients with tumors. The company was founded in 2009 and is headquartered in Guayaquil, Ecuador.

A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors.